{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:53:31Z","timestamp":1791024811811,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.amjmed.2005.01.073","type":"journal-article","created":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T07:30:18Z","timestamp":1123572618000},"page":"808-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Treatment of hepatitis C"],"prefix":"10.1016","volume":"118","author":[{"given":"Andrew I.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2005.01.073_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.7326\/0003-4819-132-4-200002150-00008","article-title":"Pathogenesis, natural history, treatment, and prevention of hepatitis C","volume":"132","author":"Liang","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib3","first-page":"17","article-title":"Liver transplantation in the United States from 1987\u20131998","author":"Seaberg","year":"1998","journal-title":"Clin Transpl."},{"key":"10.1016\/j.amjmed.2005.01.073_bib4","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2105\/AJPH.86.5.655","article-title":"Viral infections in short-term injection drug users","volume":"86","author":"Garfein","year":"1996","journal-title":"Am J Public Health"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2005.01.073_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0168-8278(99)80381-X","article-title":"Hepatitis C virus infection in the United States","volume":"31","author":"Alter","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib7","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/hep.510310329","article-title":"Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)","volume":"31","author":"Murphy","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib8","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJM199606273342602","article-title":"Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection","volume":"334","author":"Conry-Cantilena","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib9","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archinte.1993.00410140095011","article-title":"Viral hepatitis in health care personnel at The Johns Hopkins Hospital. The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection","volume":"153","author":"Thomas","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.7326\/0003-4819-120-9-199405010-00005","article-title":"Hepatitis C virus infection in spouses of patients with type C chronic liver disease","volume":"120","author":"Akahane","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib11","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hep.510310328","article-title":"Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women","volume":"31","author":"Conte","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00005792-200103000-00006","article-title":"Commercial tattooing as a potentially important source of hepatitis C infection. Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status","volume":"80","author":"Haley","year":"2001","journal-title":"Medicine (Baltimore)"},{"issue":"RR-19","key":"10.1016\/j.amjmed.2005.01.073_bib13","first-page":"1","article-title":"Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease","volume":"47","year":"1998","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"10.1016\/j.amjmed.2005.01.073_bib14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7326\/0003-4819-141-9-200411020-00013","article-title":"Testing for hepatitis C virus infection should be routine for persons at increased risk for infection","volume":"141","author":"Alter","year":"2004","journal-title":"Ann Intern Med"},{"issue":"RR-3","key":"10.1016\/j.amjmed.2005.01.073_bib15","first-page":"1","article-title":"Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus","volume":"52","author":"Alter","year":"2003","journal-title":"MMWR Recomm Rep."},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2005.01.073_bib16","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1002\/hep.510260703","article-title":"Hepatitis C","volume":"26","author":"Hoofnagle","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib17","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/hep.510290424","article-title":"The long-term outcomes of patients with compensated hepatitis C virus- related cirrhosis and history of parenteral exposure in the United States","volume":"29","author":"Hu","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib18","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.073_bib19","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hep.510310131","article-title":"Is an \u201ca la carte\u201d combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?","volume":"31","author":"Poynard","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib22","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib23","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib24","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.073_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib26","first-page":"3","article-title":"Management of hepatitis C","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib27","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib28","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-137-12-200212170-00009","article-title":"Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection","volume":"137","author":"Alberti","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(86)90883-4","article-title":"Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver","volume":"1","author":"Maharaj","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.073_bib30","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib31","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1155\/2000\/107982","article-title":"Appropriateness of liver biopsy","volume":"14","author":"Poynard","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1056\/NEJM199107113250205","article-title":"A long-term study of hepatitis C virus replication in non-A, non-B hepatitis","volume":"325","author":"Farci","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/hep.1840210306","article-title":"Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C","volume":"21","author":"Barrera","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib35","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","article-title":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin","volume":"340","author":"Kenny-Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","article-title":"Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response","volume":"98","author":"Missale","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.amjmed.2005.01.073_bib37","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0140-6736(95)91691-1","article-title":"Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection","volume":"346","author":"Diepolder","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.073_bib38","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00042737-199604000-00006","article-title":"The natural history of chronic hepatitis C infection","volume":"8","author":"Strader","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.073_bib40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.510270333","article-title":"Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity","volume":"27","author":"Mathurin","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2000-9258","article-title":"Fibrosis in patients with chronic hepatitis C","volume":"20","author":"Poynard","year":"2000","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.amjmed.2005.01.073_bib42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-122-3-199502010-00002","article-title":"Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes","volume":"122","author":"Pawlotsky","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib44","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/gast.1997.v112.pm9041265","article-title":"New insights into the mechanisms of interferon alfa","volume":"112","author":"Tilg","year":"1997","journal-title":"Gastroenterology"},{"issue":"3 Suppl 1","key":"10.1016\/j.amjmed.2005.01.073_bib45","doi-asserted-by":"crossref","first-page":"83S","DOI":"10.1002\/hep.510260715","article-title":"Therapy of hepatitis C","volume":"26","author":"Carithers","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib46","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","article-title":"Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial","volume":"321","author":"Di Bisceglie","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib47","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","article-title":"Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial","volume":"321","author":"Davis","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(97)06088-1","article-title":"Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C","volume":"351","author":"Reichard","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2005.01.073_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib50","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMoa011232","article-title":"Treatment of acute hepatitis C with interferon alfa-2b","volume":"345","author":"Jaeckel","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib51","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0016-5085(03)00668-1","article-title":"Acute hepatitis C","volume":"125","author":"Gerlach","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1590-8658(03)00007-0","article-title":"Natural course of acute hepatitis C","volume":"35","author":"Santantonio","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.amjmed.2005.01.073_bib53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/hep.20196","article-title":"Short-term interferon-alfa therapy for acute hepatitis C","volume":"39","author":"Nomura","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib55","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1053\/jlts.2002.31748","article-title":"A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation","volume":"8","author":"Crippin","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.amjmed.2005.01.073_bib56","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0168-8278(01)00179-9","article-title":"Hepatitis C and liver transplantation","volume":"35","author":"Berenguer","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib57","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0168-8278(03)00310-6","article-title":"Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation","volume":"39","author":"Forns","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib58","first-page":"359A","article-title":"Efficacy of peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C previously unresponsive to interferon-based therapy","volume":"36","author":"Krawitt","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib59","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib60","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0016-5085(03)83604-1","article-title":"Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: A trial of prior nonresponders to intereron monotherapy or combination therapy and in combination therapy relapsers: Final results","volume":"124","author":"Jacobson","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib61","first-page":"125","article-title":"Successful retreatment of peginterferon nonresponder patients with chronic hepatitis C with high dose consensus interferon induction therapy","volume":"126","author":"Kaiser","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib62","first-page":"S1165","article-title":"End of treatment response for PEG-IFN + weight-based ribavirin nonresponders retreated with IFN alfacon-1 + weight-based ribavirin","volume":"126","author":"Leevy","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib63","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1086\/520144","article-title":"Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS)","volume":"29","author":"Staples","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2005.01.073_bib64","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.amjmed.2005.01.073_bib65","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons","volume":"351","author":"Chung","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib66","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2005.01.073_bib67","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients","volume":"292","author":"Carrat","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2005.01.073_bib68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/hep.20107","article-title":"Treatment of chronic hepatitis C in HIV\/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin","volume":"39","author":"Brau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib69","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/infdis\/162.3.638","article-title":"A phase 1 study of ribavirin in human immunodeficiency virus-infected patients","volume":"162","author":"Roberts","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amjmed.2005.01.073_bib70","first-page":"1137","article-title":"The course of hepatitis C virus infection after liver transplantation","volume":"20","author":"Feray","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib71","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/gut.44.4.575","article-title":"Hepatitis C virus recurrence after liver transplantation","volume":"44","author":"Bizollon","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2005.01.073_bib72","first-page":"97","article-title":"Hepatitis C virus infection following liver transplantation","volume":"4","author":"Gane","year":"1998","journal-title":"Viral Hepatol Rev"},{"key":"10.1016\/j.amjmed.2005.01.073_bib73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00004836-200308000-00013","article-title":"Recurrent hepatitis C following liver transplant","volume":"37","author":"Saab","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib74","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/gast.2002.32418","article-title":"The association between hepatitis C infection and survival after orthotopic liver transplantation","volume":"122","author":"Forman","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib75","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/jhep.2002.33993","article-title":"Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients","volume":"36","author":"Berenguer","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib76","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib77","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/gut.52.2.283","article-title":"Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence","volume":"52","author":"Bizollon","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.amjmed.2005.01.073_bib78","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/jhep.2002.36162","article-title":"A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C","volume":"36","author":"Shakil","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib79","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jhep.2003.12.015","article-title":"Treatment of recurrent hepatitis C after liver transplantation","volume":"40","author":"Dumortier","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.amjmed.2005.01.073_bib80","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1016\/j.transproceed.2003.10.083","article-title":"Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation","volume":"35","author":"Mukherjee","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.amjmed.2005.01.073_bib81","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin","volume":"77","author":"Rodriguez-Luna","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.amjmed.2005.01.073_bib82","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/hep.1840200402","article-title":"Interferon-alpha therapy for hepatitis C virus infection after liver transplantation","volume":"20","author":"Wright","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.amjmed.2005.01.073_bib83","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/lt.20157","article-title":"Outcomes of acute rejection after interferon therapy in liver transplant recipients","volume":"10","author":"Saab","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.amjmed.2005.01.073_bib84","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hep.20065","article-title":"Hepatitis C: development of new drugs and clinical trials: promises and pitfalls: summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003","volume":"39","author":"Pawlotsky","year":"2004","journal-title":"Hepatology"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305003359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934305003359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:39:00Z","timestamp":1757579940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934305003359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0002934305003359"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.073","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hepatitis C","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2005.01.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}